A Phase I, Open Label, Multicenter Trial of Oral Azacitidine (CC-486) Plus R-CHOP in Patients with High-Risk, Previously Untreated Diffuse Large B-Cell Lymphoma, Grade 3B Follicular Lymphoma, or Transformed Lymphoma

被引：0
|
作者：
Martin, Peter
Bartlett, Nancy L.
Rivera, Ildefonso Ismael Rodriguez
Revuelta, Maria
Chavez, Julio C.
Reagan, John L.
Smith, Sonali M.
LaCasce, Ann S.
Zhang, Lei
Zhai, Merry
Wu, Chengqing
Leonard, John P.
Cerchietti, Leandro
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
192
引用
收藏
页数：2
相关论文
共 50 条
  • [31] A phase I study of IV aflibercept (Afl) in combination with R-CHOP in untreated patients (pts) with B-cell lymphoma
    Kuhnowski, F.
    Thieblemont, C.
    Jardin, F.
    Broussais-Guillemot, F.
    Meignan, M.
    Cabecadas, J.
    Gaulard, P.
    Tilly, H.
    Oprea, C.
    Haioun, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [32] Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter phase II HOVON trial
    Chamuleau, Martine E. D.
    Burggraaff, Coreline N.
    Nijland, Marcel
    Bakunina, Katerina
    Mous, Rogier
    Lugtenburg, Pieternella J.
    Dierickx, Daan
    van Imhoff, Gustaaf W.
    Vermaat, Joost S. P.
    Marijt, Eric A. F.
    Visser, Otto
    Mandigers, Caroline
    Bilgin, Yavuz M.
    Beeker, Aart
    Durian, Mark F.
    van Rees, Bas P.
    Bohmer, Lara H.
    Tick, Lidwine W.
    Boersma, Rinske S.
    Snijders, Tjeerd J. F.
    Schouten, Harry C.
    Koene, Harry R.
    de Jongh, Eva
    Hijmering, Nathalie
    Diepstra, Arjan
    van de Berg, Anke
    Arens, Anne I. J.
    Huijbregts, Julia
    Hoekstra, Otto
    Zijlstra, Josee M.
    de Jong, Daphne
    Kersten, Marie Jose
    HAEMATOLOGICA, 2020, 105 (12) : 2805 - 2812
  • [33] Phase 3 trial of subcutaneous epcoritamab plus R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.
    Sehn, Laurie Helen
    Chamuleau, Martine
    Lenz, Georg
    Clausen, Michael
    Haioun, Corinne
    Izutsu, Koji
    Davies, Andrew John John
    Zhu, Jun
    Oki, Toshiko
    Szafer-Glusman, Edith
    Conlon, Rebekah
    Chiou, Hueiyu
    Ipe, David
    Elliott, Brian
    Wu, Jun
    Salles, Gilles A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [34] Epcoritamab plus R-CHOP in Patients With Previously Untreated (1L) High-Risk Diffuse Large B-Cell Lymphoma, Including Double-Hit/Triple-Hit Lymphoma: Updated EPCORE NHL-2 Data
    Falchi, Lorenzo
    Clausen, Michael Roost
    Offner, Fritz
    de Vos, Sven
    Brody, Joshua
    Linton, Kim M.
    Snauwaert, Sylvia
    Cordoba, Raul
    Wu, Jun
    Bykhovski, Irina
    Rana, Ali
    Belada, David
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S431 - S432
  • [35] RANDOMIZED PHASE II STUDY OF R-CHOP PLUS ENZASTAURIN VERSUS R-CHOP IN THE FIRST-LINE TREATMENT OF PATIENTS WITH INTERMEDIATE AND HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) - PRELIMINARY ANALYSIS
    Hainsworth, J. D.
    Arrowsmith, E. R.
    Mccleod, M.
    Fayad, L. E.
    Hamid, O.
    Davis, L.
    Lin, B.
    ANNALS OF ONCOLOGY, 2011, 22 : 107 - 107
  • [36] Glofitamab Plus R-CHOP induces high response rates and a favorable safety profile in patients with previously untreated Diffuse Large B-Cell Lymphoma (DLBCL): results from a Phase Ib study
    Topp, M.
    Tani, M.
    Dickinson, M.
    Ghosh, N.
    Santoro, A.
    Pinto, A.
    Bosch, F.
    Fox, C. P.
    Lopez Guillermo, A.
    Carlucci, C.
    Wu, C.
    Humphrey, K.
    Baumlin, P.
    Barrett, M.
    Qayum, N.
    Morschhauser, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 207 - 207
  • [37] Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study
    Topp, Max S.
    Tani, Monica
    Dickinson, Michael
    Ghosh, Nilanjan
    Santoro, Armando
    Pinto, Antonio
    Bosch, Francesc
    Fox, Christopher P.
    Lopez-Guillermo, Armando
    Carlucci, Claudia
    Wu, Chun
    Humphrey, Kathryn
    Baumlin, Pauline
    Barrett, Martin
    Qayum, Naseer
    Morschhauser, Franck
    BLOOD, 2022, 140 : 1775 - 1777
  • [38] Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab plus Lenalidomide plus R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma
    Vitolo, Umberto
    Nowakowski, Grzegorz S.
    Burke, John M.
    Fox, Christopher P.
    Trneny, Marek
    Chiappella, Annalisa
    Waldron-Lynch, Maeve
    Wagner, Steve
    Pachori, Alok
    Lenz, Georg
    BLOOD, 2022, 140 : 6618 - 6620
  • [39] S1918: A Phase II/III Randomized Study of R-Minichop with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements
    Brem, Elizabeth A.
    Li, Hongli
    Beaven, Anne W.
    Caimi, Paolo F.
    Cerchietti, Leandro
    Alizadeh, Ash A.
    Olin, Rebecca L.
    Henry, Norah Lynn
    Dilon, Hildy
    Little, Richard F.
    Laubach, Cara
    Leblanc, Michael L.
    Friedberg, Jonathan W.
    Smith, Sonali M.
    BLOOD, 2021, 138
  • [40] Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma
    Leonard, John P.
    Kolibaba, Kathryn S.
    Reeves, James A.
    Tulpule, Anil
    Flinn, Ian W.
    Kolevska, Tatjana
    Robles, Robert
    Flowers, Christopher R.
    Collins, Robert
    DiBella, Nicholas J.
    Papish, Steven W.
    Venugopal, Parameswaran
    Horodner, Andrew
    Tabatabai, Amir
    Hajdenberg, Julio
    Park, Jaehong
    Neuwirth, Rachel
    Mulligan, George
    Suryanarayan, Kaveri
    Esseltine, Dixie-Lee
    de Vos, Sven
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (31) : 3538 - +
12345